Skip Navigation

European Heart Journal 2002 23(23):1809-1840; doi:10.1053/euhj.2002.3385
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow An erratum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (449)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Ruzyllo, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Ruzyllo, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Task Force Reports

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Micheal E. Bertrand, Chairf1, Maarten L. Simoons, Keith A.A. Fox, Lars C. Wallentin, Christian W. Hamm, Eugene McFadden, Pim J. De Feyter, Giuseppe Specchia and Witold Ruzyllo

Received August 19, 2002; accepted August 21, 2002

f1 Correspondence: Dr Michel Bertrand, Department of Cardiology, Hopital Cardiologique, Boulevard du Pr Leclercq, 59037 Lille, France.

References

  1. Davies MJ, Richardson PJ, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377–381[Abstract/Free Full Text]
  2. Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J. 1995;16:3–7[Abstract/Free Full Text]
  3. Davies M. The composition of coronary artery plaque. N Engl J Med. 1997;336:1312–1313[Free Full Text]
  4. Task force on the management of acute myocardial infarction of the European Society of Cardiology, Acute myocardial infarction: prehospital and in-hospital management, Eur Heart J
  5. J Am Coll Cardiol. 2000;36:959–969[Free Full Text]
  6. Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970–1062[Free Full Text]
  7. Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102:1193–1209[Free Full Text]
  8. Hall R. Guidelines on the management of unstable angina. Heart. 2001;85:132[Free Full Text]
  9. Verstraete M, Prentice CR, Samama M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest. 2000;117:1755–1770[Abstract/Free Full Text]
  10. Schwartz PJ, Breithardt G, Howard AJ, Julian DG, Rehnqvist Ahlberg N. Task Force Report: The legal implications of medical guidelines. A Task Force of the European Society of Cardiology. Eur Heart J. 1999;20:1152–1157[Abstract/Free Full Text]
  11. Battler A. European Heart Survey of Acute Coronary syndromes. Eur Heart J. 2002;23:1190–1201[Abstract/Free Full Text]
  12. Fox K, Goodman S, Klein W, Brieger D, Steg P, Dabbous O, Avezum A. Managements of acute coronary syndromes. Variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177–1189[Abstract/Free Full Text]
  13. Am Heart J. 2001;141:190–199[CrossRef][Web of Science][Medline]
  14. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373–377[CrossRef][Web of Science][Medline]
  15. Fuster VBL, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250[Web of Science][Medline]
  16. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126–2146[Abstract/Free Full Text]
  17. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–1275[Free Full Text]
  18. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–372[Free Full Text]
  19. Burke APFA, Tang AL. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276–1282[Abstract/Free Full Text]
  20. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996;94:2013–2020[Free Full Text]
  21. Farb ABA, Tang AL. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354–1363[Abstract/Free Full Text]
  22. Arbustini EDBB, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269–272[Abstract/Free Full Text]
  23. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 1995;91:2844–2850[Free Full Text]
  24. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994;90:775–778[Abstract/Free Full Text]
  25. Kaartinen M, van der Wal A, van der Loos C. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol. 1998;32:606–612[Abstract/Free Full Text]
  26. Arbustini E, De Servi S, Bramucci E. Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol. 1995;75:675–682[CrossRef][Web of Science][Medline]
  27. Arbustini E, Morbini P, De Servi S. Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group. G Ital Cardiol. 1996;26:623–633[Medline]
  28. Toschi VGR, Lettino M, Fallon JT. Tissue factor predicts the thrombogenicity of human atherosclerotic components. Circulation. 1997;95:594–599[Abstract/Free Full Text]
  29. Willerson JTGP, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198–205[Abstract/Free Full Text]
  30. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;63:114E–120E[CrossRef][Medline]
  31. Falk E, Fuster V. Angina pectoris and disease progression. Circulation. 1995;92:2033–2035[Free Full Text]
  32. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671[Free Full Text]
  33. van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol. 1998;31:1534–1539[Abstract/Free Full Text]
  34. Lee TH, Cook EF, Weisberg M, Sargent RK, Wilson C, Goldman L. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med. 1985;145:65–69[Abstract/Free Full Text]
  35. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 1998;31:3–11[CrossRef][Web of Science][Medline]
  36. Fisch C. The clinical ECG; sensitivity and specificity. : Elsevier; 1997.
  37. Savonitto S, Ardissino D, Granger CB. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707–713[Abstract/Free Full Text]
  38. Rouan GW, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman L. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). Am J Cardiol. 1989;64:1087–1092[CrossRef][Web of Science][Medline]
  39. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature. J Gen Intern Med. 1990;5:365–373[Web of Science][Medline]
  40. Pozen MW, D'Agostino RB, Selker HP, Sytkowski PA, Hood WB Jr. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease. A prospective multicenter clinical trial. N Engl J Med. 1984;310:1273–1278[Abstract]
  41. Davies E, Gawad Y, Takahashi M. Analytical performance and clinical utility of a sensitive immunoassay for determination of human cardiac troponin I. Clin Biochem. 1997;30:479–490[CrossRef][Web of Science][Medline]
  42. Katus HA, Looser S, Hallermayer K. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem. 1992;38:386–393[Abstract/Free Full Text]
  43. Jaffe AS, Ravkilde J, Roberts R. It's time for a change to a troponin standard. Circulation. 2000;102:1216–1220[Free Full Text]
  44. Giannitsis E, Muller-Bardorff M, Kurowski V. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211–217[Abstract/Free Full Text]
  45. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997;96:2953–2958[Abstract/Free Full Text]
  46. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354–1359[Abstract]
  47. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163–168[Abstract/Free Full Text]
  48. McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey SW. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. Clin Chem. 1997;43:976–982[Abstract/Free Full Text]
  49. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol. 1996;106:118–123[Web of Science][Medline]
  50. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation. 2000;102:1221–1226[Abstract/Free Full Text]
  51. Cannon CP, Weintraub WS, Demopoulos LA. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887[Abstract/Free Full Text]
  52. Lancet. 1999;354:708–715[CrossRef][Web of Science][Medline]
  53. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol. 2001;38:979–986[Abstract/Free Full Text]
  54. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999;45:1104–1121[Abstract/Free Full Text]
  55. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–452[Abstract/Free Full Text]
  56. Campbell RWF, Turpie AGG, Maseri A. Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol. 1998;21:314–322[Web of Science][Medline]
  57. Braunwald E, Jones RH, Mark DB. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation. 1994;90:613–622[Abstract/Free Full Text]
  58. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195–1206[Free Full Text]
  59. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410–414[Free Full Text]
  60. van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol. 1995;25:1286–1292[Abstract]
  61. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group. J Intern Med. 1993;234:293–301[Web of Science][Medline]
  62. Diderholm E, Andren B, Frostfeldt G. The Fast Revascularization during InStability in Coronary artery d. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease. The FRISC II ECG substudy. Eur Heart J. 2002;23:41–49[Abstract/Free Full Text]
  63. Circulation. 1994;89:1545–1556[Abstract/Free Full Text]
  64. Andersen K, Eriksson P. Ischaemia detected by continuous on-line vectocardiographic monitoring predictes unfavourable outcome in patients admitted with probable unstable coronary artery disease. Coron Artery Dis. 1996;7:753–760[Web of Science][Medline]
  65. Gottlieb SO, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. 1986;314:1214–1219[Abstract]
  66. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol. 1989;13:1495–1502[Abstract]
  67. Larsson H, Areskog M, Areskog NH. The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction. Eur Heart J. 1995;16:888–893[Abstract/Free Full Text]
  68. Wilcox I, Ben Freedman S, Kelly DT, Harris PJ. Clinical significance of silent ischemia in unstable angina pectoris. Am J Cardiol. 1990;65:1313–1316[CrossRef][Web of Science][Medline]
  69. Patel DJ, Holdright DR, Knight CJ. Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. Heart. 1996;75:222–228[Abstract/Free Full Text]
  70. Akkerhuis KM, Klootwijk PA, Lindeboom W. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J. 2001;22:1997–2006[Abstract/Free Full Text]
  71. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol. 1998;81:1405–1410[CrossRef][Web of Science][Medline]
  72. Ottani F, Galvani M, Nicolini FA. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917–927[CrossRef][Web of Science][Medline]
  73. Morrow DA, Cannon CP, Rifai N. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405–2412[Abstract/Free Full Text]
  74. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus HA. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992;327:146–150[Abstract]
  75. Pettersson T, Ohlsson O, Tryding N. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death. Eur Heart J. 1992;13:1387–1392[Abstract/Free Full Text]
  76. Ravkilde J, Hansen AB, Horder M, Jorgensen PJ, Thygesen K. Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2·5-year follow-up study in 156 consecutive patients. Cardiology. 1992;80:143–151[Web of Science][Medline]
  77. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ. 1996;313:262–264[Abstract/Free Full Text]
  78. Wu AH, Abbas SA, Green S. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol. 1995;76:970–972[CrossRef][Web of Science][Medline]
  79. Lindahl B. Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Ups J Med Sci. 1996;101:193–232[Medline]
  80. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation. 1996;93:1651–1657[Abstract/Free Full Text]
  81. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 1997;29:43–48[Abstract]
  82. Antman EM, Tanasijevic MJ, Thompson B. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342–1349[Abstract/Free Full Text]
  83. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. Circulation. 1997;96:2578–2585[Abstract/Free Full Text]
  84. Galvani M, Ottani F, Ferrini D. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation. 1997;95:2053–2059[Abstract/Free Full Text]
  85. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J. 1997;18:762–770[Abstract/Free Full Text]
  86. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–1147[Abstract/Free Full Text]
  87. Holmvang LAK, Andersen K, Dellborg M. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease. Am J Cardiol. 1999;83:667–674[CrossRef][Web of Science][Medline]
  88. Dellborg M, Andersen K. Key factors in the identification of the high-risk patient with unstable coronary artery disease: clinical findings, resting 12-lead electrocardiogram, and continuous electrocardiographic monitoring. Am J Cardiol. 1997;80:35E–39E[CrossRef][Medline]
  89. Hamm CW, Heeschen C, Goldmann B. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623–1629[Abstract/Free Full Text]
  90. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. 1999;354:1757–1762[CrossRef][Web of Science][Medline]
  91. Newby LK, Ohman EM, Christenson RH. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy. Circulation. 2001;103:2891–2896[Abstract/Free Full Text]
  92. Morrow DA, Antman EM, Tanasijevic M. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000;36:1812–1817[Abstract/Free Full Text]
  93. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation. 1997;96:4204–4210[Abstract/Free Full Text]
  94. Becker RCC, Bovill E. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol. 1996;78:142–147[Web of Science][Medline]
  95. Pollak H, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis? Thromb Haemost. 1991;66:406–409[Web of Science][Medline]
  96. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537–547[Abstract/Free Full Text]
  97. de Lemos JA, Morrow DA, Bentley JH. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021[Abstract/Free Full Text]
  98. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107–2113[Abstract/Free Full Text]
  99. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J. 2001;22:1226–1234[Abstract/Free Full Text]
  100. Ardissino D, Merlini PA, Gamba G. Thrombin activity and early outcome in unstable angina pectoris. Circulation. 1996;93:1634–1639[Abstract/Free Full Text]
  101. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost. 1998;79:491–494[Web of Science][Medline]
  102. Meade TW. Routine measurement of fibrinogen concentration. Clinically feasible. BMJ. 1993;307:1562[Free Full Text]
  103. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischaemic heart disease in women. BMJ. 1996;312:1581[Free Full Text]
  104. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J. 1995;16:31–34
  105. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J. 1990;11:525–528[Abstract/Free Full Text]
  106. Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3–9[CrossRef][Web of Science][Medline]
  107. Kruskal JCP, Franks J, Kirsch R. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Eng J Med. 1987;22:1361–1365
  108. Wilcox I, Freedman SB, Allman KC. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. J Am Coll Cardiol. 1991;18:677–683[Abstract]
  109. Wilcox I, Ben Freedman SB, Li JN, Harris PJ, Kelly DT. Comparison of exercise stress testing with ambulatory electrocardiographic monitoring in the detection of myocardial ischemia after unstable angina pectoris. Am J Cardiol. 1991;67:89–91[CrossRef][Web of Science][Medline]
  110. Launbjerg J, Fruergaard P, Jacobsen HL, Madsen JK. Long-term risk factors from non-invasive evaluation of patients with acute chest pain, but without myocardial infarction. Eur Heart J. 1995;16:30–37[Abstract/Free Full Text]
  111. Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. Int J Cardiol. 1993;39:131–142[CrossRef][Web of Science][Medline]
  112. Amanullah AM, Lindvall K, Bevegard S. Exercise echocardiography after stabilization of unstable angina: correlation with exercise thallium-201 single photon emission computed tomography. Clin Cardiol. 1992;15:585–589[Web of Science][Medline]
  113. Amanullah AM, Lindvall K. Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment. Clin Cardiol. 1992;15:417–423[Web of Science][Medline]
  114. Amanullah AM, Lindvall K, Bevegard S. Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment. Int J Cardiol. 1993;39:71–78[CrossRef][Web of Science][Medline]
  115. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment [published erratum appears in J Am Coll Cardiol 1991 Sep; 18(3):889]. J Am Coll Cardiol. 1991;17:1053–1057[Abstract]
  116. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1987;316:977–984[Abstract]
  117. Telford AMWC. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1:1225–1228[Web of Science][Medline]
  118. Lubsen JTJ. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT. Am J Cardiol. 1987;60:18A–25A[CrossRef][Medline]
  119. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259–2263[Abstract/Free Full Text]
  120. Eur. Heart J. 1985;6:199–226[Abstract/Free Full Text]
  121. Kaplan KDR, Parker M, Przybylek J, Teagarden JR, Lesch M. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol. 1983;51:694–698[CrossRef][Web of Science][Medline]
  122. DePace N, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med. 1982;142:1806–1809[Abstract/Free Full Text]
  123. Roubin GSHP, Eckhardt I. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust N Z J Med. 1982;12:598–602[Web of Science][Medline]
  124. Curfman G, Heinsimr JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective randomized trial. Circulation. 1983;67:276–282[Abstract/Free Full Text]
  125. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol. 1991;41:5–9[CrossRef][Web of Science][Medline]
  126. May DCPJ, Podma JJ, Black WH. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med. 1987;317:805–809[Abstract]
  127. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol. 1984;54:1–7[Web of Science][Medline]
  128. Thadani U, Hamilton SF, Olsen E. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med. 1986;105:485–492[Abstract/Free Full Text]
  129. Lancet. 2002;359:1269–1275[CrossRef][Web of Science][Medline]
  130. Theroux P, Taeymans Y, Morissette D. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol. 1985;5:717–722[Abstract]
  131. Parodi O, Simonetti I, Michelassi C. Comparison of verapamil and propanolol therapy for angina pectoris at rest. A randomized, multiple crossover, controlled trial in the coronary care unit. Am J Cardiol. 1986;57:899–906[CrossRef][Web of Science][Medline]
  132. Smith NLRG, Reiberge GE, Psaty BM. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 1998;32:1305–1311[Abstract/Free Full Text]
  133. Gibson RS, Young PM, Boden WE, Schechtman K, Roberts R. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study. Am J Cardiol. 1987;60:203–209[CrossRef][Web of Science][Medline]
  134. Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies. Am J Cardiol. 2000;86:275–279[CrossRef][Web of Science][Medline]
  135. Held PYS, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J. 1989;299:1187–1192[Abstract/Free Full Text]
  136. Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620–625[Abstract/Free Full Text]
  137. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295–1297[CrossRef][Web of Science][Medline]
  138. Boden WE, van Gilst WH, Scheldewaert RG. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet. 2000;355:1751–1756[CrossRef][Web of Science][Medline]
  139. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–815[Abstract/Free Full Text]
  140. Theroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111[Abstract]
  141. Lancet. 1996;347:561–568[CrossRef][Web of Science][Medline]
  142. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942[CrossRef][Web of Science][Medline]
  143. Antman EM, McCabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]
  144. Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable Angina/Non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta- analysis. Circulation. 1999;100:1602–1608[Abstract/Free Full Text]
  145. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J. 2002;23:308–314[Abstract/Free Full Text]
  146. Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invas Cardiol. 2000;12:E10–13
  147. N Engl J Med. 1996;335:775–782[Abstract/Free Full Text]
  148. Fox KA. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol. 1999;84:26M–31M[Web of Science][Medline]
  149. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88:2045–2048[Abstract/Free Full Text]
  150. Cairns JA, Singer J, Gent M. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol. 1989;5:239–246[Web of Science][Medline]
  151. BMJ. 2002;324:71–86[Abstract/Free Full Text]
  152. Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990;82:17–26[Abstract/Free Full Text]
  153. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502[Abstract/Free Full Text]
  154. Lancet. 1996;348:1329–1339[CrossRef][Web of Science][Medline]
  155. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–629[Abstract/Free Full Text]
  156. Leebeek FWG, Boersma E, Cannon CP, van de Werf FJJ, Simoons ML. Oral glycoprotein IIb/IIIareceptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J. 2002;23:444–457[Free Full Text]
  157. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  158. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  159. Lancet. 1998;352:87–92[Web of Science][Medline]
  160. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  161. Lancet. 1997;349:1422–1428[CrossRef][Web of Science][Medline]
  162. Lancet. 2000;356:2037–2044[CrossRef][Web of Science][Medline]
  163. Topol EJ, Moliterno DJ, Herrmann HC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894[Abstract/Free Full Text]
  164. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  165. N Engl J Med. 1998;338:1498–1505[Abstract/Free Full Text]
  166. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  167. N Engl J Med. 1998;339:436–443[Abstract/Free Full Text]
  168. Circulation. 1998;97:2386–2395[Abstract/Free Full Text]
  169. Lancet. 2001;357:1915–1924[CrossRef][Web of Science][Medline]
  170. Circulation. 2002;105:316–321[Abstract/Free Full Text]
  171. Boersma E, Harrington R, Moliterno D. Platelet glycoproteinIIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198[CrossRef][Web of Science][Medline]
  172. Roffi M, Chew DP, Mukherjee D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767–2771[Abstract/Free Full Text]
  173. Steinhubl SR, Talley JD, Braden GA. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572–2578[Abstract/Free Full Text]
  174. Madan M, Tcheng JE. Update on abciximab readministration during percutaneous coronary interventions. Curr Interv Cardiol Rep. 2000;2:244–249[Medline]
  175. Madan M, Kereiakes DJ, Hermiller JB. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol. 2000;85:435–440[CrossRef][Web of Science][Medline]
  176. Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J Invas Cardiol. 2000;12:E5–9
  177. James S, Armstrong P, Califf R. Safety and efficiency of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J. 2002;23:1538–1545[Abstract/Free Full Text]
  178. Circulation. 1993;87:38–52[Abstract/Free Full Text]
  179. Karlsson JE, Berglund U, Bjorkholm A, Ohlsson J, Swahn E, Wallentin L. Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group. Am Heart J. 1992;124:1419–1426[CrossRef][Web of Science][Medline]
  180. Schreiber TL, Macina G, McNulty A. Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction. Am J Cardiol. 1989;64:840–844[CrossRef][Web of Science][Medline]
  181. Schreiber TL, Macina G, Bunnell P. Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms. Am Heart J. 1990;120:248–255[CrossRef][Web of Science][Medline]
  182. Schreiber TL, Rizik D, White C. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation. 1992;86:1407–1414[Abstract/Free Full Text]
  183. Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
  184. Lancet. 1999;354:708–715[CrossRef][Web of Science][Medline]
  185. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation. 1998;97:26–33[Abstract/Free Full Text]
  186. Serruys PW, van Hout B, Bonnier H. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673–681[CrossRef][Web of Science][Medline]
  187. Lincoff AM, Califf RM, Anderson KM. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol. 1997;30:149–156[Abstract]
  188. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 1998;82:36P–42P[CrossRef][Web of Science][Medline]
  189. Lancet. 1998;352:87–92[Web of Science][Medline]
  190. Mehta SR, Yusuf S, Peters RJ. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533[CrossRef][Web of Science][Medline]
  191. Bjessmo S, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class. Am Heart J. 2001;141:9–14[CrossRef][Web of Science][Medline]
  192. Dyke CM, Bhatia D, Lorenz TJ. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg. 2000;70:866–871[Abstract/Free Full Text]
  193. Bizzarri F, Scolletta S, Tucci E. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001;122:1181–1185[Abstract/Free Full Text]
  194. Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg. 2000;69:762–764[Abstract/Free Full Text]
  195. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. Online J Curr Clin Trials. 1994;:
  196. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2. Online J Curr Clin Trials. 1994;:
  197. JAMA. 1997;277:715–721[Abstract/Free Full Text]
  198. CABRI Investigators, First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation.Circulation, 1996, 93, 847
  199. Lancet. 1993;341:573–580[CrossRef][Web of Science][Medline]
  200. King SB 3rd, Lembo NJ, Weintraub WS. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med. 1994;331:1044–1050[Abstract/Free Full Text]
  201. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med. 1994;331:1037–1043[Abstract/Free Full Text]
  202. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol. 1993;22:1060–1067[Abstract]
  203. Serruys PW, Unger F, Sousa JE. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117–1124[Abstract/Free Full Text]
  204. Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol. 2001;38:41–48[Abstract/Free Full Text]
  205. Eur Heart J. 1993;14:969–988[Free Full Text]
  206. Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol. 1997;80:55E–60E[CrossRef][Medline]
  207. Lancet. 1990;336:827–830[CrossRef][Web of Science][Medline]
  208. BMJ. 2002;324:71–86[Abstract/Free Full Text]
  209. Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718[Abstract/Free Full Text]
  210. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430–436[Abstract/Free Full Text]
  211. Stenestrand, U, Wallentin, L, Early revascularization and 1-year survival in 14-days survivors of acute myocardial infarction: a prospective cohort study. Lancet, 2002, 359, 1805, 11
  212. N Engl J Med. 1991;325:293–302[Abstract]
  213. N Engl J Med. 1992;327:685–691[Abstract]
  214. Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838[CrossRef][Web of Science][Medline]
  215. Rabbani RTE. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res. 1999;41:402–417[Abstract/Free Full Text]
  216. Yusuf S, Kostis JB, Pitt B. ACE inhibitors for myocardial infarction and unstable angina. Lancet. 1993;341:829[Web of Science][Medline]
  217. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  218. Dagenais GR, Yusuf S, Bourassa MG. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104:522–526[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
G. Montalescot, H. Drexler, R. Gallo, T. Pearson, M. Thoenes, and D. L. Bhatt
Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
Eur. Heart J., November 2, 2009; 30(22): 2733 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Montalescot, D. Brieger, K. A. Eagle, F. A. Anderson Jr, G. FitzGerald, M. S. Lee, Ph. G. Steg, A. Avezum, S. G. Goodman, J. M. Gore, et al.
Unprotected left main revascularization in patients with acute coronary syndromes
Eur. Heart J., October 1, 2009; 30(19): 2308 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. Montalescot, G. Cayla, J.-P. Collet, S. Elhadad, F. Beygui, H. Le Breton, R. Choussat, F. Leclercq, J. Silvain, F. Duclos, et al.
Immediate vs Delayed Intervention for Acute Coronary Syndromes: A Randomized Clinical Trial
JAMA, September 2, 2009; 302(9): 947 - 954.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
K E Joynt, L Huynh, J V Amerena, D B Brieger, S G Coverdale, J M Rankin, A Soman, and D P Chew
Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes
Heart, September 1, 2009; 95(17): 1442 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D Blendea, M Blendea, J Banker, and C A McPherson
Troponin T elevation after implanted defibrillator discharge predicts survival
Heart, July 15, 2009; 95(14): 1153 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D Brieger, K A A Fox, G FitzGerald, K A Eagle, A Budaj, A Avezum, C B Granger, B Costa, F A Anderson Jr, P. G Steg, et al.
Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events
Heart, June 1, 2009; 95(11): 888 - 894.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. P. Giugliano, J. A. White, C. Bode, P. W. Armstrong, G. Montalescot, B. S. Lewis, A. van `t Hof, L. G. Berdan, K. L. Lee, J. T. Strony, et al.
Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes
N. Engl. J. Med., May 21, 2009; 360(21): 2176 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EchocardiogrHome page
M. Richardson-Lobbedez, S. Marechaux, C. Bauters, J. Darchis, J. L. Auffray, J. J. Bauchart, J. M. Aubert, T. H. LeJemtel, M. Lesenne, E. Van Belle, et al.
Prognostic importance of tissue Doppler-derived diastolic function in patients presenting with acute coronary syndrome: a bedside echocardiographic study
Eur J Echocardiogr, September 1, 2008; 9(5): 594 - 598.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Ong, A. Athanasiadis, S. Hill, H. Vogelsberg, M. Voehringer, and U. Sechtem
Coronary Artery Spasm as a Frequent Cause of Acute Coronary Syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study
J. Am. Coll. Cardiol., August 12, 2008; 52(7): 523 - 527.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
C D Miller, G J Fermann, C J Lindsell, K W Mahaffey, W F Peacock, C V Pollack, J E Hollander, D B Diercks, W B Gibler, and J W Hoekstra on behalf of the EMCREG-International
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions
Emerg. Med. J., August 1, 2008; 25(8): 492 - 497.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
F. M. Sanfilippo, M. S. T. Hobbs, M. W. Knuiman, and J. Hung
Impact of New Biomarkers of Myocardial Damage on Trends in Myocardial Infarction Hospital Admission Rates from Population-based Administrative Data
Am. J. Epidemiol., July 15, 2008; 168(2): 225 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. Sullivan and N. Amarshi
Dual antiplatelet therapy with clopidogrel and aspirin
Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1134 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 670S - 707S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Devlin, J. M. Gore, J. Elliott, N. Wijesinghe, K. A. Eagle, A. Avezum, W. Huang, D. Brieger, and for the GRACE Investigators
Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events
Eur. Heart J., May 2, 2008; 29(10): 1275 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M.-C. Simeoni, P. Barragan, F. Dignat-George, and F. Paganelli
Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1404 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.-P. Bassand
The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes
Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C22 - C29.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Weber, O. Bazzino, J. L. Navarro Estrada, J. J. Fuselli, F. Botto, D. Perez de Arenaza, H. Mollmann, H. N. Nef, A. Elsasser, and C. W. Hamm
N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission
J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1188 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. H. Lee, M. Tan, A. T. Yan, R. T. Yan, D. Fitchett, E. A. Grima, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndromes (ACS) Re
Use of Cardiac Catheterization for Non-ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk: Reasons Why Physicians Choose Not to Refer Their Patients
Arch Intern Med, February 11, 2008; 168(3): 291 - 296.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Marcassa, J. J. Bax, F. Bengel, B. Hesse, C. L. Petersen, E. Reyes, R. Underwood, and on behalf of the European Council of Nuclear Cardi
Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: a position statement
Eur. Heart J., February 2, 2008; 29(4): 557 - 563.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
O H Dabbous, F A Anderson Jr, J M Gore, K A Eagle, K A A Fox, R H Mehta, R J Goldberg, G Agnelli, P G Steg, and for the GRACE Investigators
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes
Heart, February 1, 2008; 94(2): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
A. K. Gitt and A. Betriu
Antiplatelet therapy in acute coronary syndromes
Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. E. Bertrand
When and how to discontinue antiplatelet therapy
Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A35 - A41.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. W. Stone, J. H. Ware, M. E. Bertrand, A. M. Lincoff, J. W. Moses, E. M. Ohman, H. D. White, F. Feit, A. Colombo, B. T. McLaurin, et al.
Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management: One-Year Results From the ACUITY Trial
JAMA, December 5, 2007; 298(21): 2497 - 2506.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Tello-Montoliu, F. Marin, J. Patel, V. Roldan, L. Mainar, V. Vicente, F. Sogorb, and G. Y.H. Lip
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis
Eur. Heart J., December 2, 2007; 28(24): 3006 - 3011.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Perez de Isla, J. Zamorano, M. Quezada, C. Almeria, J. L. Rodrigo, V. Serra, J. C. Garcia Rubira, A. F. Ortiz, and C. Macaya
Functional mitral regurgitation after a first non-ST-segment elevation acute coronary syndrome: contribution to congestive heart failure
Eur. Heart J., December 1, 2007; 28(23): 2866 - 2872.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
W. Otter, M. Winter, W. Doering, E. Standl, and O. Schnell
C-Reactive Protein in Diabetic and Nondiabetic Patients With Acute Myocardial Infarction
Diabetes Care, December 1, 2007; 30(12): 3080 - 3082.
[Full Text] [PDF]

Home page
 HeartHome page
A. Norhammar, J. Lindback, L. Ryden, L. Wallentin, U. Stenestrand, and on behalf of the Register of Information and Knowl
Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission
Heart, December 1, 2007; 93(12): 1577 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. F. Storey, S. Husted, R. A. Harrington, S. Heptinstall, R. G. Wilcox, G. Peters, M. Wickens, H. Emanuelsson, P. Gurbel, P. Grande, et al.
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1852 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
W. B Meijboom, N. R Mollet, C. A Van Mieghem, A. C Weustink, F. Pugliese, N. van Pelt, F. Cademartiri, E. Vourvouri, P. de Jaegere, G. P Krestin, et al.
64-Slice CT coronary angiography in patients with non-ST elevation acute coronary syndrome
Heart, November 1, 2007; 93(11): 1386 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A.O. Kraaijeveld, S.C.A. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. Putter, T.J.C. van Berkel, L. Nagelkerken, J.W. Jukema, et al.
CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms
Circulation, October 23, 2007; 116(17): 1931 - 1941.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. M. Eggers, B. Lagerqvist, P. Venge, L. Wallentin, and B. Lindahl
Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality
Circulation, October 23, 2007; 116(17): 1907 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. C. Wollert, T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler, et al.
Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome
Circulation, October 2, 2007; 116(14): 1540 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al.
Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1132 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Thielmann, M. Neuhauser, A. Marr, U. Herold, M. Kamler, P. Massoudy, and H. Jakob
Predictors and Outcomes of Coronary Artery Bypass Grafting in ST Elevation Myocardial Infarction
Ann. Thorac. Surg., July 1, 2007; 84(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660.
[Full Text] [PDF]

Home page
 BMJHome page
R. J G Peters, S. Mehta, and S. Yusuf
Acute coronary syndromes without ST segment elevation
BMJ, June 16, 2007; 334(7606): 1265 - 1269.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Montalescot, J. Dallongeville, E. Van Belle, S. Rouanet, C. Baulac, A. Degrandsart, E. Vicaut, and for the OPERA Investigators
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
Eur. Heart J., June 2, 2007; 28(12): 1409 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 CirculationHome page
K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al.
Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Circulation, May 15, 2007; 115(19): 2549 - 2569.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Hamon, J. Riddell, and M. Hamon
Letter by Hamon et al Regarding Article, "Coronary Multidetector Computed Tomography in the Assessment of Patients With Acute Chest Pain"
Circulation, May 8, 2007; 115(18): e448 - e448.
[Full Text] [PDF]

Home page
 JAMAHome page
K. A. A. Fox, P. G. Steg, K. A. Eagle, S. G. Goodman, F. A. Anderson Jr, C. B. Granger, M. D. Flather, A. Budaj, A. Quill, J. M. Gore, et al.
Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
JAMA, May 2, 2007; 297(17): 1892 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. V. Rao, J. A. Eikelboom, C. B. Granger, R. A. Harrington, R. M. Califf, and J.-P. Bassand
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Eur. Heart J., May 2, 2007; 28(10): 1193 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. T. Yan, R. T. Yan, M. Tan, A. Casanova, M. Labinaz, K. Sridhar, D. H. Fitchett, A. Langer, and S. G. Goodman
Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better
Eur. Heart J., May 1, 2007; 28(9): 1072 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
O. Manfrini and R. Bugiardini
Barriers to clinical risk scores adoption
Eur. Heart J., May 1, 2007; 28(9): 1045 - 1046.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C. J. Boos, S. K. Soor, D. Kang, and G. Y.H. Lip
Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes
Eur. Heart J., May 1, 2007; 28(9): 1092 - 1101.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
P. Mad, H. Domanovits, C. Fazelnia, K. Stiassny, G. Russmuller, A. Cseh, G. Sodeck, T. Binder, G. Christ, T. Szekeres, et al.
Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction
QJM, April 1, 2007; 100(4): 203 - 210.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, A. Montinaro, and G. Di Sciascio
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1272 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Recio-Mayoral, M. Chaparro, B. Prado, R. Cozar, I. Mendez, D. Banerjee, J. C. Kaski, J. Cubero, and J. M. Cruz
The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention: The RENO Study
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1283 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Renda, R. Di Pillo, A. D'Alleva, A. Sciartilli, M. Zimarino, E. De Candia, R. Landolfi, G. Di Giammarco, A. Calafiore, and R. De Caterina
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery
Haematologica, March 1, 2007; 92(3): 366 - 373.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. J Lenzen, W. J M Scholte op Reimer, S. S Pedersen, E. Boersma, W. Maier, P. Widimsky, M. L Simoons, N. F Mercado, W. Wijns, and on behalf of the investigators of the Euro Heart S
The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation
Heart, March 1, 2007; 93(3): 339 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Wong, S Murray, A Ramsewak, A Robinson, C van Heyningen, and E Rodrigues
Raised cardiac troponin T levels in patients without acute coronary syndrome
Postgrad. Med. J., March 1, 2007; 83(977): 200 - 205.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. W. Stone, M. E. Bertrand, J. W. Moses, E. M. Ohman, A. M. Lincoff, J. H. Ware, S. J. Pocock, B. T. McLaurin, D. A. Cox, M. Z. Jafar, et al.
Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial
JAMA, February 14, 2007; 297(6): 591 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Held, P. Tornvall, and U. Stenestrand
Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery
Eur. Heart J., February 1, 2007; 28(3): 316 - 325.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
F.-J. Neumann and H. J. Buttner
Underuse of revascularisation in acute coronary syndromes
Heart, February 1, 2007; 93(2): 147 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
F.-J. Neumann, A. Kastrati, and G. Schwarzer
New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective
Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A4 - A10.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
K A A Fox, F A Anderson Jr, O H Dabbous, P G Steg, J Lopez-Sendon, F Van de Werf, A Budaj, E P Gurfinkel, S G Goodman, D Brieger, et al.
Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)
Heart, February 1, 2007; 93(2): 177 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
D. Dudek, A. Dziewierz, B. Chyrchel, L. Polonski, J. Legutko, and J. S. Dubiel
Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A25 - A31.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. R. Bhattacharyya, L. Perkins-Porras, D. L. Whitehead, and A. Steptoe
Psychological and clinical predictors of return to work after acute coronary syndrome
Eur. Heart J., January 2, 2007; 28(2): 160 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 QJMHome page
G. Ramsay, M. Podogrodzka, C. McClure, and K.A.A. Fox
Risk prediction in patients presenting with suspected cardiac pain: the GRACE and TIMI risk scores versus clinical evaluation
QJM, January 1, 2007; 100(1): 11 - 18.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. Gibbons and T. D. Miller
Noninvasive Risk Stratification After Myocardial Infarction: New Evidence, New Questions
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2468 - 2470.
[Full Text] [PDF]

Home page
 QJMHome page
K. Bindra, C. Berry, J. Rogers, N. Stewart, M. Watts, J. Christie, S.M. Cobbe, and H. Eteiba
Abnormal haemoglobin levels in acute coronary syndromes.
QJM, December 1, 2006; 99(12): 851 - 862.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Y. H. Lip and M. Karpha
Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: The Need for Consensus and a Management Guideline
Chest, December 1, 2006; 130(6): 1823 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. W. Stone, B. T. McLaurin, D. A. Cox, M. E. Bertrand, A. M. Lincoff, J. W. Moses, H. D. White, S. J. Pocock, J. H. Ware, F. Feit, et al.
Bivalirudin for Patients with Acute Coronary Syndromes.
N. Engl. J. Med., November 23, 2006; 355(21): 2203 - 2216.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Perez de Isla, J. Zamorano, M. Quezada, C. Almeria, J. L. Rodrigo, V. Serra, J. C. Garcia Rubira, A. F. Ortiz, and C. Macaya
Prognostic significance of functional mitral regurgitation after a first non-ST-segment elevation acute coronary syndrome
Eur. Heart J., November 2, 2006; 27(22): 2655 - 2660.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M Heras, H Bueno, A Bardaji, A Fernandez-Ortiz, H Marti, J Marrugat, and on behalf of the DESCARTES Investigators
Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry
Heart, November 1, 2006; 92(11): 1571 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Goser, M. Andrassy, S. J. Buss, F. Leuschner, C. H. Volz, R. Ottl;, S. Zittrich;, N. Blaudeck, S. E. Hardt, G. Pfitzer, et al.
Cardiac Troponin I but Not Cardiac Troponin T Induces Severe Autoimmune Inflammation in the Myocardium
Circulation, October 17, 2006; 114(16): 1693 - 1702.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Mandelzweig, A. Battler, V. Boyko, H. Bueno, N. Danchin, G. Filippatos, A. Gitt, D. Hasdai, Y. Hasin, J. Marrugat, et al.
The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004
Eur. Heart J., October 1, 2006; 27(19): 2285 - 2293.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. E. Bertrand and E. Van Belle
Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G59 - G63.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. de Winter
Commentary on Clinical Guidelines and Practice: In Search of the Truth by Dean J. Kereiakes and Elliott M. Antman
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1136 - 1138.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, Ph. G. Steg, M. Slama, O. Milleron, J.-P. Collet, P. Henry, et al.
A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 931 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
C. P Gale, C. Kashinath, and P. Brooksby
The association between hyperglycaemia and elevated troponin levels on mortality in acute coronary syndromes
Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 80 - 83.
[Abstract] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow An erratum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (449)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Ruzyllo, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Ruzyllo, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?